# Selective Treatment According to Molecular Subtype of Prostate Cancer

> **NCT03696186** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Castration-resistant Prostate Cancer
- Prostate Cancer Metastatic

## Interventions

- **DRUG:** Luminal type-1
- **DRUG:** Luminal type-2
- **DRUG:** Neuroendocrine type-1
- **DRUG:** Neuroendocrine type-2
- **DRUG:** Atypical type-1
- **DRUG:** Atypical type-2

## Key facts

- **NCT ID:** NCT03696186
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-01
- **Primary completion:** 2022-08
- **Final completion:** 2023-08
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03696186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03696186, "Selective Treatment According to Molecular Subtype of Prostate Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03696186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*